myeloproliferative neoplasms

032 — Potentially Practice-Changing Drugs Approved by the FDA in 2023

https://www.pharmacytimes.com/view/eleven-potentially-practice-changing-drugs-were-approved-by-the-fda-in-2023 Daprodustat (Jesduvroq; GSK) is an oral medication for treating anemia in adults undergoing hemodialysis due to chronic kidney disease (CKD). Unlike traditional treatments that rely on iron supplementation and erythropoiesis-stimulating…

Continue Reading032 — Potentially Practice-Changing Drugs Approved by the FDA in 2023

029 — Iptacopan for PNH, Casgevy and Lyfgenia for Sickle Cell Disease, SGT-003 in Duchenne Muscular Dystrophy, New Fingerstick Blood Collection Device

Here is information on the latest US FDA approvals, the week of December 2 -  December 8, 2023 Iptacopan (Fabhalta) for PNH The FDA has approved iptacopan (Fabhalta) as the first…

Continue Reading029 — Iptacopan for PNH, Casgevy and Lyfgenia for Sickle Cell Disease, SGT-003 in Duchenne Muscular Dystrophy, New Fingerstick Blood Collection Device

018 — Ojjaara for Anemia in Myelofibrosis, Resmetirom for NASH, COVID-19 Vaccine Update, Phenylephrine, Patisiran in ATTR-CM

Here is information on the latest US FDA approvals, the week of September 11 –  September 15, 2023.FDA Approves Ojjaara (Momelotinib) for Anemia in MyelofibrosisThe FDA has approved Ojjaara (momelotinib)…

Continue Reading018 — Ojjaara for Anemia in Myelofibrosis, Resmetirom for NASH, COVID-19 Vaccine Update, Phenylephrine, Patisiran in ATTR-CM